WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Amycretin

Governed registry record

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

    DOI: 10.1016/s0140-6736(25)01185-7

    Source identity and connection checked by Codex (AI).

  2. Beyond weight loss: multisystem benefits of obesity medications.

    DOI: 10.1016/s2213-8587(26)00100-2PMID: 42208956

    Source identity and connection checked by Codex (AI).

  3. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.

    DOI: 10.1210/endrev/bnaf036

    Source identity and connection checked by Codex (AI).

  4. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.

    DOI: 10.1016/j.ebiom.2025.105862

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Dahl K
  • Toubro S
  • Dey S
  • Duque do Vale R
  • Flint A
  • Gasiorek A
  • Heydorn A
  • Jastreboff AM
  • Key C
  • Petersen SB
  • Vegge A
  • Adelborg K
  • Kuhre RE
  • Ballarín-González B
  • Brand CL
  • Glendorf T
  • Madsen KG
  • Hjøllund KR
  • Hogendorf WFJ
  • Ipsen DH
  • Lundh S
  • Kruse T
  • Secher A
  • Raun K
  • Son JW
  • le Roux CW
  • Blüher M
  • Nauck MA
  • Lim S
  • Savas M
  • Kuckuck S
  • Boon MR
  • van Rossum EFC